News|Articles|November 3, 2025

ASN Kidney Week 2025 Preview: 5 Phase 3 Trials to Know

Kidney Week 2025 showcases groundbreaking clinical trials and FDA approvals, marking a transformative era in nephrology and kidney disease treatment.

When American Society of Nephrology (ASN) Kidney Week 2025 convenes in Houston, Texas, from November 5-9, it will do so at a pivotal time for the field. For decades, progress in nephrology was measured in slow, incremental gains. However, the last decade has brought forth evidence of shifting momentum, with decades of foundational research translating into meaningful clinical advances across diseases once defined by limited options.

Related to this article

November 14th, 2026

Omalizumab Linked to 0 Epinephrine Use in Alpha-Gal Syndrome

No patients with alpha-gal syndrome needed epinephrine for a food reaction during omalizumab therapy in a 64-patient cohort presented at ACAAI 2026.

November 14th, 2026

Kidney Compass: Platform Trials in IgA Nephropathy and Glomerular Disease

Suceena Alexander, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss platform trial design in IgA nephropathy and beyond.

November 14th, 2026

FDA Approves Obinutuzumab (Gazyva) for Primary Membranous Nephropathy

Approval of obinutuzumab for adults with PMN follows MAJESTY, where 37% vs 6% achieved complete remission at week 104 vs tacrolimus.

November 13th, 2026

Omalizumab, Remibrutinib Show Similar Early CSU Gains in Indirect Analysis

A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.

November 12th, 2026

Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control

Post hoc analyses at ACAAI 2026 show 41.7% of patients-maintained CSU control and quality of life 16 weeks after stopping omalizumab.

November 11th, 2026

Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD

Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.

November 10th, 2026

Don't Miss a Beat: What Lp(a)HORIZON and ZEUS Teach About Clinical Trial Science

Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.

Image Credit: US Food and Drug Administration

November 9th, 2026

Asundexian Receives FDA Approval for Secondary Stroke Prevention

The FDA approved asundexian with antiplatelet therapy after noncardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.